What happened
Anumana's ECG-AI LEF and Eko's ELEFT, both retrained from a Mayo Clinic algorithm, flag a left ventricular ejection fraction of 40% or less from an electrocardiogram. Singapore's Agency for Care Effectiveness (ACE) reviewed the evidence in a brief published on 30 April 2026, and it writes that AI-ECG uses deep learning. ACE drew on two randomized trials, four prospective observational studies and one cost-effectiveness study. Against echocardiography, sensitivity ranged from 76.5% to 100% and specificity from 78.3% to 97%. Negative predictive value was 98% to 100%, and positive predictive value was 16.4% to 43.3%. No serious adverse events were reported. In the EAGLE trial, low ejection fraction was found in 0.9% of patients whose clinicians saw the AI results, against 0.6% of controls (p=0.057). In a Nigerian trial, cardiovascular events did not differ between arms. All-cause deaths were higher in its AI arm, from non-cardiovascular causes. ACE found that evidence for clinical utility remains limited. Asian patients made up 0% to 19.9% of study populations. ACE notes that the brief rests on a limited literature search and does not appraise the studies.
Sources
-
Assessment report, by authors with no tie to the system.
Overall, Eko and Anumana AI-ECG tools were found to be safe with moderate accuracy in detecting LVEF ≤40%.
Findings from the EAGLE RCT showed that compared to usual care, the use of Anumana ECG-AI LEF did not result in significant changes in the detection of low LVEF (≤40%) or clinical management.
Details
AI system
- Workflow
-
Anumana's algorithm analyzed standard 12-lead ECGs, and Eko's ELEFT analyzed single-lead ECG and heart sounds from the Eko DUO digital stethoscope. Each tool returned a binary result for an ejection fraction of 40% or less.
Follow-up
- Conditions for replication
-
Patients are adults at risk of heart failure. Clinicians use the result with their own evaluation and clinical judgment, and an echocardiogram still confirms heart failure.
Entry details
- Sector
-
Healthcare.
- Purpose
-
Anumana and Eko Health built ECG-AI LEF and ELEFT to help clinicians identify adults at risk of heart failure whose left ventricular ejection fraction is 40% or less.
30 more questions not yet checked
model, release, provider, role, configuration, inputs and outputs, autonomy, human oversight, beneficiaries, reach, distribution and access, duration, every measurement question, every money question, ownership and control, dependencies, cross-border connections, geopolitical implications, replication attempts, availability, institutional decision, grounds, action and result, success criterion, every evidence question, observed or intended, alternative assessments, related entries, other identifiers, category mappings.
Cite this record
Peter H. Vartanian. (2026). ECG-AI LEF and ELEFT flag weak heart pumps with moderate accuracy (AIBD-1163). Artificial Intelligence Benefits Database, edition of 1 November 2026. https://petervartanian.xyz/aibd/records/AIBD-1163.html (archived at https://doi.org/10.7910/DVN/AADSII, version 7.0)